Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) announced its quarterly earnings results on Wednesday. The biotechnology company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($1.32) by $0.64, Zacks reports.
Ascendis Pharma A/S Stock Performance
NASDAQ:ASND traded up $1.59 on Friday, hitting $144.08. 551,280 shares of the stock were exchanged, compared to its average volume of 433,669. Ascendis Pharma A/S has a 52 week low of $111.09 and a 52 week high of $161.00. The stock has a market capitalization of $8.74 billion, a price-to-earnings ratio of -17.83 and a beta of 0.64. The company's 50-day moving average price is $132.41 and its 200 day moving average price is $132.34.
Wall Street Analysts Forecast Growth
ASND has been the topic of several recent analyst reports. Stifel Nicolaus boosted their target price on shares of Ascendis Pharma A/S from $200.00 to $207.00 and gave the company a "buy" rating in a research note on Friday, November 15th. The Goldman Sachs Group upped their price objective on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a "buy" rating in a research note on Thursday. Wedbush reiterated an "outperform" rating and issued a $181.00 target price on shares of Ascendis Pharma A/S in a research note on Friday, November 15th. TD Cowen reduced their target price on Ascendis Pharma A/S from $160.00 to $153.00 and set a "buy" rating on the stock in a report on Friday, November 15th. Finally, StockNews.com raised Ascendis Pharma A/S from a "sell" rating to a "hold" rating in a report on Wednesday, November 20th. Two equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $193.43.
Check Out Our Latest Stock Analysis on Ascendis Pharma A/S
About Ascendis Pharma A/S
(
Get Free Report)
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.
Featured Stories
Before you consider Ascendis Pharma A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ascendis Pharma A/S wasn't on the list.
While Ascendis Pharma A/S currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
